市場調査レポート

次世代シークエンシング市場

Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)

発行 Kalorama Information 商品コード 324189
出版日 ページ情報 英文 391 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
次世代シークエンシング市場 Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
出版日: 2015年01月23日 ページ情報: 英文 391 Pages
概要

世界の次世代シークエンシング市場は急増しています。

当レポートでは、世界の次世代シークエンシング市場について調査し、システム・消耗品・サービス市場の規模と予測、地域別の分析、地域分布、主要企業の市場シェア、プラットフォームごとのブランド所有、およりDNAシークエンシング市場などについてまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 シークエンシング技術

  • サンガ―シークエンシング
  • 次世代シークエンシング
  • MPSS(Massively Parallel Signature Sequencing)
  • パイロシークエンシング
  • 454 シークエンシング技術
  • SBS(Sequencing by Synthesis)法
  • SOLiD(Supported Oligonucleotide Ligation and Detection)
  • イオントレントシークエンシング
  • tSMS(True Single Molecule Sequencing )
  • SMRT(Single Molecule Real Time)シークエンシング
  • DNAナノボールシークエンシング
  • ナノポアシークエンシング
  • その他のシークエンシング技術
  • サンプル調製
  • 情報技術
  • ワークフローもしくはプラットフォームの回答サンプル

第4章 シークエンシング用途

  • 研究、ドラッグディスカバリーおよび開発
  • シークエンシングの診断用途
  • 直販ジェネリック検査産業

第5章 契約:シークエンシング企業

  • シークエンシング企業の投資・財務契約
  • その他企業との契約
  • シークエンスング企業の買収
  • その他の主な合意

第6章 シークエンシングの診断への応用:市場促進因子・課題

  • 技術ハードルの克服:サンプル調製・データ分析
  • 次世代シークエンシング市場の促進因子
  • 研究市場に販売する企業が直面する課題と障壁
  • 診断市場に販売する企業が直面する課題と障壁
  • 将来の展望

第7章 DNAシークエンシング市場分析

  • DNAシークエンシングの市場概要
  • シークエンシング市場:地域分布
  • ブランドの所有
  • DNAシークエンシング市場:研究vs.臨床用途

第8章 企業プロファイル:次世代シークエンシング企業

図表リスト

目次
Product Code: KLI5458715

No business planner in biotechnology or diagnostic equipment or services can ignore the trend of sequencing, and particularly next-generation sequencing. This technology has enabled a wide scope of research and genetic analysis. The promise of DNA sequencing has attracted many companies, researchers, and investors. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. More than ever, marketers of advanced equipment and those investing in those companies need a resource to identify the specific developments in sequencing.

This report, Next-Generation Sequencing Markets (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Trends, Platforms, Applications, Brand Ownership) provides evidence of the promise and current excitement in the DNA sequencing market.

Tracking the Path of Sequencing to the Clinical Lab

Many improvements in sequencing technology are needed in order to make sequencing-based diagnostic tests widely available and used by all physicians, though DNA sequencing has successfully penetrated the research market. Applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories will continue to grow. The first next generation sequencing system and IVD tests have been cleared by the FDA, and more will follow. Some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model.

Reasons for Optimism

Over the years, the DNA sequencing field has gone through periods of excitement (referred to as hype) by some, followed by periods of disappointment as the hoped for advances have not materialized as quickly as hoped or promised. The promise of DNA sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events:

  • The DNA sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company's full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year.
  • Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D
  • Companies are raising money: In just the first part of January 2015, In addition to Roche's investment in Foundation Medicine, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing.
  • Agreements with pharmaceutical companies: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one.
  • Sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina's MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform.

These are just selected highlights of recent activities in this rapidly changing market. Because of these trends, Kalorama expects the market to grow from its current size of 2.2 billion to 5.6 billion. The entire market is broken out in detail in Kalorama's Next Generation Sequencing Markets.

This Informative Analysis Helps You Track These Developments, with Reliable Market Estimates

The report provides the world markets for next generation sequencing in U.S. dollars for 2014 to 2018. As part of its analysis, the following data points are provided.

  • DNA Sequencing Systems Market Size and Forecast
  • DNA Sequencing Consumables Market, Size and Forecast
  • DNA Sequencing Services Market, Size and Forecast
  • Sequencing Market - Geographical Distribution (US, Europe, Asia, ROW)
  • Market Share by Major Competitor
  • Brand Ownership by Platform
  • DNA Sequencing Market - Research versus Clinical Applications

The sequencing market includes capillary electrophoresis sequencing systems (based on the early Sanger sequencing method) and also the rapidly growing next generation sequencing market. The market estimate includes both sequencing instruments plus consumables.

Who's Doing What In Sequencing: Superior Company Profiling

Competitor participation is an important part of the shaping of this market and the report devotes considerable detail to competitive analysis. Driven by the promise of clinical diagnostic applications, the DNA sequencing market is growing rapidly and companies are raising money. In early 2015 and throughout a busy 2014 there were many investments in next generation sequencing companies and companies with products or services related to next generation sequencing. Pharmaceutical companies, for example, have recognized the potential benefits of next generation sequencing as a research and development tool. The report provides product information and financial information for over 100 companies that are involved in next generation sequencing including:

  • 10X Genomics
  • 23andMe, Inc.
  • Adaptive Biotechnologies Corporation
  • Admera Health (A GENEWIZ Company)
  • Advanced Biological Laboratories, S.A.
  • Agilent Technologies Inc.
  • AltheaDx Diagnostics, Inc.
  • Ambry Genetics Corp.
  • Aperiomics, Inc.
  • Appistry, Inc.
  • Asuragen, Inc.
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • Base4 Innovation Ltd.
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • BGI-Shenzhen
  • Bina Technologies, Inc. (Acquired by Roche)
  • BioDiscovery, Inc.
  • Bioinnovation Solutions SA
  • Biomatters Ltd.
  • bioMérieux SA
  • bioTheranostics (A bioMérieux Company)
  • Cancer Genetics, Inc.
  • CareDx, Inc.
  • Caris Life Sciences
  • Chronix Biomedical, Inc.
  • CLC bio (A QIAGEN Company)
  • Complete Genomics (A BGI Company)
  • Courtagen Life Sciences, Inc.
  • Cypher Genomics, Inc.
  • DioGenix, Inc.
  • DNA Electronics Ltd.
  • DNASTAR, Inc.
  • Eurofins Genomics
  • Eurofins MWG Operon Inc. (A Eurofins Genomics Company)
  • Expression Analysis, Inc. (A Quintiles Company)
  • Fluidigm Corporation
  • Foundation Medicine, Inc.
  • GATC Biotech AG
  • GenapSys
  • GenDx
  • Gene by Gene, Ltd.
  • Genection, Inc. (An Invivoscribe Company)
  • GeneDx
  • GeneInsight, Inc.
  • GENEWIZ Inc.
  • Genia Technologies, Inc. (Acquired by Roche)
  • GenoLogics Life Sciences Software
  • Genomic Diagnostics Technologies
  • GenomOncology
  • Genoptix (A Novartis Company)
  • GigaGen, Inc.
  • GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.)
  • Good Start Genetics, Inc.
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • Igenbio, Inc.
  • Illumina, Inc.
  • Innovations Exchange Pte Ltd (INEX)
  • iGene™ Diagnostics Pte Ltd (an INEX Company)
  • Insight Genetics, Inc.
  • InSilixa, Inc.
  • Intel Corporation
  • Intelligent Bio-Systems, Inc. (A QIAGEN Company)
  • Invivoscribe Technologies, Inc.
  • iRepertoire, Inc.
  • Knome Inc.
  • Laboratory Corporation of America (LabCorp)
  • LaserGen, Inc.
  • LifeCodexx AG (Subsidiary of GATC Biotech AG)
  • Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
  • Mayo Medical Laboratories and Mayo Clinic
  • MolecularMD Corporation
  • Multiplicom NV
  • Nabsys, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • NetBio, Inc.
  • NewGene Ltd.
  • NextCODE Health
  • NobleGen Biosciences, Inc.
  • N-of-One, Inc.
  • OncoDNA SA
  • OncoPlex Diagnostics (OncoPlexDx)
  • Oncospire Genomics
  • One Lambda, Inc. (A Thermo Fisher Scientific Brand)
  • Oxford Gene Technology
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences
  • Parabase Genomics
  • Pathway Genomics Corporation
  • PerkinElmer, Inc.
  • Personal Genome Diagnostics, Inc.
  • Personalis, Inc.
  • PicoSeq
  • Population Genetics Technologies Ltd.
  • QIAGEN N.V.
  • QuantuMDx Group
  • Quest Diagnostics
  • RainDance Technologies, Inc.
  • Response Genetics, Inc.
  • Roche
  • SeqLL, LLC
  • Sequenta, Inc.
  • Siemens Healthcare Diagnostics
  • Siemens
  • Sirona Genomics
  • SoftGenetics, LLC
  • Stratos Genomics Inc.
  • Swift Biosciences, Inc.
  • Symbiodx
  • Sysmex Inostics GmbH
  • Thermo Fisher Scientific, Inc.
  • Vela Diagnostics
  • WaferGen Biosystems, Inc.
  • ZS Genetics, Inc.

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Market Overview
  • Prognosis for Growth of the DNA Sequencing Market

TWO: INTRODUCTION

  • Overview and History of DNA Sequencing
  • Point-of-View

THREE: SEQUENCING TECHNOLOGY

  • Sanger Sequencing
  • Next-Generation Sequencing
  • Massively Parallel Signature Sequencing (MPSS)
  • Pyrosequencing
  • 454 Technology
  • Sequencing by Synthesis (SBS)
  • Supported Oligonucleotide Ligation and Detection (SOLiD)
  • Ion Torrent Sequencing
  • True Single Molecule Sequencing (tSMS)
  • Single Molecule Real Time (SMRT) Sequencing
  • DNA Nanoball Sequencing
  • Nanopore Sequencing
  • Other Sequencing Technologies
  • Sample Preparation
  • Information Technology
  • Sample-to-Answer Workflows or Platforms

FOUR: SEQUENCING APPLICATIONS

  • Research, Drug Discovery and Development
  • Diagnostic Applications of Sequencing
    • Cancer Diagnostics
    • Genetic Analysis - Inherited Disorders, Prenatal Diagnostics, Postnatal Diagnostics
    • Infectious Disease Diagnostics
    • Human Leukocyte Antigen (HLA) Testing
    • Other Diagnostic Applications of Sequencing
  • Direct-to-Consumer Genetic Testing Industry

FIVE: DEALS - SEQUENCING COMPANIES

  • Investments and Financing Agreements for Sequencing Companies
  • Agreements with Other Companies
  • Acquisitions of Sequencing Companies
  • Selected Other Agreements

SIX: APPLYING SEQUENCING TO DIAGNOSTICS - MARKET DRIVERS AND CHALLENGES

  • Overcoming Technology Hurdles - Sample Preparation and Data Analysis
  • Next Generation Sequencing Market Drivers
  • Issues and Hurdles Faced by Companies Selling to the Research Market
  • Issues and Hurdles Faced by Companies in the Diagnostics Market
  • Future Prospects

SEVEN: DNA SEQUENCING MARKET ANALYSIS

  • DNA Sequencing Market Overview
  • Sequencing Market - Geographical Distribution
  • Brand Ownership
  • DNA Sequencing Market - Research versus Clinical Applications

EIGHT: COMPANY PROFILES: NEXT GENERATION SEQUENCING COMPANIES

  • 10X Genomics
  • 23andMe, Inc.
  • Adaptive Biotechnologies Corporation
  • Admera Health (A GENEWIZ Company)
  • Advanced Biological Laboratories, S.A
  • Agilent Technologies Inc.
    • Recent Revenue History
    • Company Overview
  • AltheaDx Diagnostics, Inc.
  • Ambry Genetics Corp.
  • Aperiomics, Inc.
  • Appistry, Inc.
  • Asuragen, Inc.
    • Diagnostic Products
    • Genomic Services
    • Clinical Lab
    • Companion Diagnostics
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • Base4 Innovation Ltd
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
    • Recent Revenue History
    • Company Overview
    • Next-Generation Sequencing - Sample Prep
    • Beckman Coulter Genomics
  • BGI-Shenzhen
  • Bina Technologies, Inc. (Acquired by Roche)
  • BioDiscovery, Inc.
  • Bioinnovation Solutions SA
  • Biomatters Ltd.
  • bioMérieux SA
    • Recent Revenue History
    • Company Overview
  • bioTheranostics (A bioMérieux Company)
  • Cancer Genetics, Inc.
    • Recent Revenue History
    • Company Overview
  • CareDx, Inc.
    • Recent Revenue History
    • Company Overview
  • Caris Life Sciences
  • Chronix Biomedical, Inc.
  • CLC bio (A QIAGEN Company)
  • Complete Genomics (A BGI Company)
  • Courtagen Life Sciences, Inc.
  • Cypher Genomics, Inc
  • DioGenix, Inc.
  • DNA Electronics Ltd.
  • DNASTAR, Inc.
  • Eurofins Genomics
  • Eurofins MWG Operon Inc. (A Eurofins Genomics Company)
  • Expression Analysis, Inc. (A Quintiles Company)
  • Fluidigm Corporation
    • Recent Revenue History
    • Company Overview
  • Foundation Medicine, Inc.
    • Recent Revenue History
    • Company Overview
  • GATC Biotech AG
  • GenapSys
  • GenDx
  • Gene by Gene, Ltd.
  • Genection, Inc. (An Invivoscribe Company)
  • GeneDx
  • GeneInsight, Inc.
  • GENEWIZ Inc.
  • Genia Technologies, Inc. (Acquired by Roche)
  • GenoLogics Life Sciences Software
  • Genomic Diagnostics Technologies
  • GenomOncology
  • Genoptix (A Novartis Company)
  • GigaGen, Inc.
  • GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.)
  • Good Start Genetics, Inc.
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • Igenbio, Inc.
  • Illumina, Inc.
    • Recent Revenue History
    • Company Overview
  • Innovations Exchange Pte Ltd (INEX)
  • iGene™ Diagnostics Pte Ltd (an INEX Company)
  • Insight Genetics, Inc.
  • InSilixa, Inc.
  • Intel Corporation
    • Recent Revenue History
    • Company Overview
  • Intelligent Bio-Systems, Inc. (A QIAGEN Company)
  • Invitae Corporation
    • Recent Revenue History
    • Company Overview
  • Invivoscribe Technologies, Inc.
  • iRepertoire, Inc.
  • Knome Inc.
  • Laboratory Corporation of America (LabCorp)
    • Recent Revenue History
    • Company Overview
  • LaserGen, Inc.
  • LifeCodexx AG (Subsidiary of GATC Biotech AG)
  • Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.)
    • Recent Revenue History
    • Company Overview
  • Mayo Medical Laboratories and Mayo Clinic
  • MolecularMD Corporation
  • Multiplicom NV
  • Nabsys, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc./NeoGenomics Laboratories
    • Recent Revenue History
    • Company Overview
  • NetBio, Inc
  • NewGene Ltd.
  • NextCODE Health
  • NobleGen Biosciences, Inc.
  • N-of-One, Inc.
  • OncoDNA SA
  • OncoPlex Diagnostics (OncoPlexDx)
  • Oncospire Genomics
  • One Lambda, Inc. (A Thermo Fisher Scientific Brand)
  • Oxford Gene Technology
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences
    • Recent Revenue History
    • Company Overview
  • Parabase Genomics
  • Pathway Genomics Corporation
  • PerkinElmer, Inc.
    • Recent Revenue History
    • Company Overview
  • Personal Genome Diagnostics, Inc.
  • Personalis, Inc.
  • PicoSeq
  • Population Genetics Technologies Ltd
  • QIAGEN N.V.
    • Recent Revenue History
    • Company Overview
  • QuantuMDx Group
  • Quest Diagnostics
  • Recent Revenue History
  • Company Overview
  • RainDance Technologies, Inc.
  • Response Genetics, Inc.
    • Recent Revenue History
    • Company Overview
  • Roche
    • Recent Revenue History
    • Company Overview
  • SeqLL, LLC
  • Sequenta, Inc
  • Siemens Healthcare Diagnostics
  • Siemens
    • Recent Revenue History
    • Company Overview
  • Sirona Genomics
  • SoftGenetics, LLC
  • Stratos Genomics Inc.
  • Swift Biosciences, Inc.
  • Symbiodx
  • Sysmex Inostics GmbH
  • Thermo Fisher Scientific, Inc.
    • Recent Revenue History
    • Company Overview
  • Vela Diagnostics
  • WaferGen Biosystems, Inc.
    • Recent Revenue History
  • Company Overview
  • ZS Genetics, Inc.

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Table 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2014 and 2019
  • Figure 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2014 and 2019

THREE: SEQUENCING TECHNOLOGY

  • Table 3-1: Sequencing Technologies and Platforms
  • Table 3-2: Selected Companies Developing/Marketing Products for NGS Sample Preparation
  • Table 3-3: Selected Companies Developing/Marketing NGS Information Technology Solutions
  • Table 3-4: Selected Companies Developing NGS Sample-to-Answer Platforms

FOUR: SEQUENCING APPLICATIONS

  • Table 4-1: Selected Companies Developing or Marketing Next Generation Sequencing
  • Products or Services for Research Applications
  • Table 4-2: Selected Pharmaceutical Companies That Made Deals to Access Next Generation Sequencing Technologies or Capabilities
  • Table 4-3: Selected Diagnostic Companies Offering Sequencing-Based Tests through Their Own CLIA-Certified Laboratory and Selected Reference Laboratories Offering Sequencing-Based Tests
  • Table 4-4: Selected Diagnostic Companies Developing or Marketing Sequencing-Based
  • Tests as Kits Sold to Clinical Laboratories
  • Table 4-5: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
  • Table 4-6: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis (Inherited Disorders, Prenatal and Postnatal Diagnostics)
  • Table 4-7: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
  • Table 4-8: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Human Leukocyte Antigen (HLA) Testing
  • Table 4-9: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications

FIVE: DEALS - SEQUENCING COMPANIES

  • Table 5-1: Selected Investment and Other Financing Agreements for Next Generation Sequencing Companies (Includes IT Companies in NGS)
  • Table 5-2: Selected Agreements between Next Generation Sequencing Companies and Other Diagnostic Companies or Clinical Laboratories (Includes IT Companies in NGS)
  • Table 5-3: Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies (Includes Contract Research Organizations Providing Services to Pharma Companies)
  • Table 5-4: Selected Company Agreements between Two Next Generation Sequencing Companies (Includes IT Companies in NGS)
  • Table 5-5: Selected Other Next-Generation Sequencing Company Agreements(Includes IT Companies in NGS)
  • Table 5-6: Selected Acquisitions of Next Generation Sequencing Companies(Includes IT Companies in NGS)
  • Table 5-7: Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations (Includes IT Companies in NGS)

SEVEN: DNA SEQUENCING MARKET ANALYSIS

  • Table 7-1: Instrument Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
  • Table 7-2: Consumables Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
  • Table 7-3: Services Revenue, DNA Sequencing Market, Worldwide, 2014 and 2019
  • Table 7-4: Total DNA Sequencing Market, Worldwide, 2014 and 2019
  • Figure 7-1: Next Generation Sequencing Market (Instruments, Consumables, Systems), 2014 vs. 2019
  • Figure 7-2: Market Share of DNA Sequencing Market, by Company
  • Table 7-5: DNA Sequencing Revenues by Geographical Region, Worldwide, 2014 and 2019 (North America, Europe, Asia, Rest of World, Total Market)
  • Figure 7-3: Next Generation Sequencing System Ownership by Country, Percentage(United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia,Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
  • Figure 7-4: Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
  • Figure 7-5: DNA Sequencing Market - Research versus Clinical Applications,2014
Back to Top